SCHEMBL3400810

SCHEMBL3400810

O=C1CCCCC12CCCCC2

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 2/20 0.40
TRIM33 Q9UPN9 2/20 0.40
ALDH1A1 P00352 1/20 0.40
GRIN1 Q05586 3/20 0.32
GRIN2A Q12879 3/20 0.32
SLC6A4 P31645 2/20 0.32
GRIN2D O15399 2/20 0.32
GRIN3B O60391 2/20 0.32
GRIN2B Q13224 2/20 0.32
GRIN2C Q14957 2/20 0.32
GRIN3A Q8TCU5 2/20 0.32
LMNA P02545 2/20 0.32
OPRK1 P41145 1/20 0.32
OPRM1 P35372 1/20 0.32
CACNA1C Q13936 1/20 0.32
TSHR P16473 1/20 0.31
CRBN Q96SW2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8837715 1.00 TRIM24 (0.40) TRIM24TRIM33ALDH1A1GRIN1GRIN2A
SCHEMBL3815762 1.00 TRIM24 (0.40) TRIM24TRIM33ALDH1A1GRIN1GRIN2A
SCHEMBL7638818 0.97 TRIM24 (0.38) TRIM24TRIM33ALDH1A1GRIN1GRIN2A
SCHEMBL3403022 0.97 TRIM24 (0.38) TRIM24TRIM33ALDH1A1GRIN1GRIN2A
SCHEMBL2775678 0.97 TRIM24 (0.37) TRIM24TRIM33ALDH1A1GRIN1GRIN2A
SCHEMBL537099 0.94 ALDH1A1 (0.33) TRIM24TRIM33ALDH1A1CRBN
SCHEMBL3389316 0.94
Bromide SCHEMBL5789681 0.92 ALDH1A1 (0.32) TRIM24TRIM33ALDH1A1
SCHEMBL2774682 0.91 CRBN (0.32) TRIM24TRIM33CRBN
SCHEMBL22470021 0.88 ALDH1A1 (0.33) TRIM24TRIM33ALDH1A1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115417989-A Preparation of degradable high-heat-resistance polyimide material 南京理工大学 2022-12-02 CN claimed
EP-0074693-B1 PERFUME COMPOSITIONS AND PERFUMED ARTICLES CONTAINING SPIRO-UNDECANONES AND -UNDECENONES AS PERFUME BASE NAARDEN INTERNATIONAL N.V. (NL) 1986-01-08 EP claimed
US-9266841-B2 Compounds GLAXO GROUP LIMITED (GB) 2016-02-23 US disclosed
US-20150299090-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2015-10-22 US disclosed
US-20150299090-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2015-10-22 US disclosed
US-20150299090-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2015-10-22 US disclosed
US-20150045375-A1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2015-02-12 US disclosed
US-8871775-B2 Compounds GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
EP-2684861-A2 Spiro compounds and pharmaceutical use thereof Japan Tobacco Inc. (JP) 2014-01-15 EP disclosed
US-20130109710-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2013-05-02 US disclosed
US-20130109710-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2013-05-02 US disclosed
US-20070155762-A1 Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase SMITHKLINE BEECHAM PLC 2007-07-05 US disclosed
US-7232902-B2 Process to prepare (1-carboxymethyl)-pyrimidinone compounds SMITHKLINE BEECHAM P.L.C. (GB) 2007-06-19 US disclosed
US-20070123549-A1 platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis SMITHKLINE BEECHAM PLC 2007-05-31 US disclosed
US-7153861-B2 For therapy of atheroscelerosis SMITHKLINE BEECHAM P.L.C. (GB) 2006-12-26 US disclosed
US-20060194788-A1 Guanidine derivatives and their use as neuropeptide ff receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2006-08-31 US disclosed
EP-1686119-A1 PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2006-08-02 EP disclosed
EP-1263740-B1 PYRIMIDINE-4-ONE DERIVATIVE AS LDL-PLA2 INHIBITOR SMITHKLINE BEECHAM PLC (GB) 2006-07-19 EP disclosed
EP-1456183-B1 PROCESS FOR PREPARING 1-(CARBOXYMETHYL)-AND 1-(AMINOCARBONYL)-PYRIMIDIN-4-ONE DERIVATES SMITHKLINE BEECHAM PLC (GB) 2006-04-19 EP disclosed
US-20040242875-A1 Novel processes SMITHKLINE BEECHAM PLC (GB) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299090-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF REN, PKD1, PKD2 TRIM24 4631/4885TRIM33 4817/4885ALDH1A1 268/4885
US-20060194788-A1 Guanidine derivatives and their use as neuropeptide ff receptor antagonists NPFFR1, OGFR, NPFFR2 TRIM24 1793/4885TRIM33 2891/4885ALDH1A1 1895/4885
US-20150045375-A1 NOVEL COMPOUNDS PLA2G7, ALOX15B, PLA2G1B TRIM24 3606/4885TRIM33 4020/4885ALDH1A1 514/4885
US-20130109710-A1 SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF REN, PKD1, PKD2 TRIM24 4631/4885TRIM33 4817/4885ALDH1A1 268/4885
US-20070155762-A1 Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase PLAT, PLA2G7, LYPLAL1 TRIM24 2400/4885TRIM33 4352/4885ALDH1A1 1423/4885
US-20070123549-A1 platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis PLA2G7, PLAT, PLA2G1B TRIM24 1973/4885TRIM33 4466/4885ALDH1A1 664/4885
US-20040242875-A1 Novel processes DHPS, FDPS, NUDT5 TRIM24 2858/4885TRIM33 2167/4885ALDH1A1 1528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.